Leerink Partners initiates coverage of ORIC Pharmaceuticals with outperform rating, $26 target
ORIC•Leerink Partners initiated coverage of ORIC Pharmaceuticals with an outperform rating and a $26 price target.
Related News
BP: Mizuho raises target price to $56 from $53
BP•
BP has no plans to shy away from the Middle East, CEO says
BP•
Fortrea sets third-quarter 2026 results release and conference call
FTRE•
Bunker Hill Mining starts surface drilling at Page property after first hole hits 15 ft of mineralization
BHLL•
Netgear: Stifel cuts target price to $30 from $36
NTGR•